Income statement
USD
Annual
| Metric | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|
| Revenue | 31M | 556K | 4M | 6M | 3M |
| Gross Profit | 28M | 60K | 531K | 1M | 677K |
| Operating Income | -4M | -7M | -2M | -127K | 316K |
| EBITDA | -4M | -9M | -2M | -126K | 318K |
| Net Income | -5M | -11M | -2M | -340K | 127K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ScripsAmerica, Inc. (SCRCQ) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +5447.5%, EPS growth of +76.8%, a dividend yield of 0.0%. What stands out right now is revenue +5447.5%, EPS +76.8%, free cash flow +132.5% with operating margin -12.3% and ROIC 388.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SCRCQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCRCQ
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SCRCQ Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SCRCQ and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.2M
-45.9% YoY
FY Net Income
$127.1K
+137.4% YoY
Free Cash Flow
-$186.4K
-75.3% YoY
Revenue Growth
+5447.5%
EPS Growth
+76.8%
Gross Margin
89.4%
Net Margin
-15.3%
Income statement
USD
| Metric | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|
| Revenue | 31M | 556K | 4M | 6M | 3M |
| Gross Profit | 28M | 60K | 531K | 1M | 677K |
| Operating Income | -4M | -7M | -2M | -127K | 316K |
| EBITDA | -4M | -9M | -2M | -126K | 318K |
| Net Income | -5M | -11M | -2M | -340K | 127K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|
| Cash & Equivalents | 454K | 47K | 14K | 468K | 172K |
| Total Assets | 6M | 2M | 2M | 2M | 631K |
| Total Liabilities | 9M | 4M | 4M | 2M | 366K |
| Shareholder Equity | -3M | -3M | -1M | -9K | 265K |
| Total Debt | 1M | 1M | 1M | 875K | 345K |
| Net Debt | 749K | 1M | 1M | 407K | 173K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
186K
-75.3% YoY
Capital Expenditures
0
Free Cash Flow
186K
-75.3% YoY
Key ratios
Gross Margin
89.4%
Operating Margin
-12.3%
Net Margin
-15.3%
ROE
162.6%
Debt / Equity
-0.37x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.